MicroTransponder, Inc. today announced United States Food and Drug Administration (FDA) Premarket Approval of the Vivistim Paired VNS™ System, which significantly improves the effectiveness of rehabilitation therapy for stroke survivors with moderate to severe upper extremity impairment six months after stroke.
August 31, 2021
· 4 min read